(NASDAQ: NVAX) Novavax's forecast annual revenue growth rate of -11.09% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 30.64%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.43%.
Novavax's revenue in 2026 is $413,796,000.On average, 11 Wall Street analysts forecast NVAX's revenue for 2026 to be $60,436,114,006, with the lowest NVAX revenue forecast at $42,415,793,441, and the highest NVAX revenue forecast at $88,003,493,193. On average, 11 Wall Street analysts forecast NVAX's revenue for 2027 to be $45,264,406,129, with the lowest NVAX revenue forecast at $34,204,795,201, and the highest NVAX revenue forecast at $71,121,298,137.
In 2028, NVAX is forecast to generate $47,974,464,407 in revenue, with the lowest revenue forecast at $25,055,255,779 and the highest revenue forecast at $60,381,681,917.